Trial Profile
An early phase II study of TSU-68 in combination with docetaxel in patients with advanced and metastatic breast cancer progressing anthracycline containing regimen.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 22 May 2018
Price :
$35
*
At a glance
- Drugs Orantinib (Primary) ; Docetaxel
- Indications Breast cancer
- Focus Therapeutic Use
- Sponsors Taiho Pharmaceutical Company
- 31 May 2016 New trial record